Literature DB >> 34169365

Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study.

Nazim Benzerdjeb1, Peggy Dartigues2, Vahan Kepenekian3, Séverine Valmary-Degano4, Eliane Mery5, Gerlinde Averous6, Anne Chevallier7, Marie-Hélène Laverriere4, Irène Villa2, Françoise Galateau Sallé8, Laurent Villeneuve9, Olivier Glehen3, Sylvie Isaac10, Juliette Hommell-Fontaine10.   

Abstract

Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. A recently described nuclear-grading system predicted survival in patients with epithelioid malignant pleural mesothelioma. The present study was undertaken to validate this grading system in epithelioid malignant peritoneal mesothelioma (EMPM) and to compare to combined grade, including nuclear atypia, mitotic count, and tumor necrosis. Cases of EMPM, from 1995 to 2018, were analyzed from 7 French institutions from RENAPE network. Solid growth, tumor necrosis, nuclear atypia, and mitotic count were evaluated by at least 3 pathologists from the RENAPATH group. The predictions in terms of OS and PFS of nuclear grade and combined grade were analyzed. Nuclear grade was computed combining nuclear atypia score and mitotic count into a grade of I-III. Another system combining nuclear atypia score, mitotic score, and tumor necrosis was evaluated and defined as a combined grade I-III. A total of 138 cases were identified. The median follow-up was 38.9 months (range: 1.1-196.6). Nuclear and combined grades III were independently associated with a shorter OS (p < 0.05), and a shorter PFS (p < 0.05). Patients with combined grade I tumors had the best overall and progression-free survivals, in comparison to nuclear grade I. In this large multicentric study, combined grade and nuclear grade were the best independent predictors of OS and PFS in EMPM. These systems should be easily described by pathologists involved into the management of malignant peritoneal mesothelioma, because of their potential therapeutic implications.

Entities:  

Keywords:  Biomarker; Histological prognostic factor; Malignant epithelioid peritoneal mesothelioma; Mesothelioma

Year:  2021        PMID: 34169365     DOI: 10.1007/s00428-021-03144-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  15 in total

1.  Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.

Authors:  Sandy Liu; Paul Staats; Michael Lee; H Richard Alexander; Allen P Burke
Journal:  Pathology       Date:  2014-12       Impact factor: 5.306

2.  Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.

Authors:  Alyssa M Krasinskas; Alain C Borczuk; Douglas J Hartman; John A Chabot; Robert N Taub; Ashish Mogal; James Pingpank; David Bartlett; Sanja Dacic
Journal:  Histopathology       Date:  2015-10-16       Impact factor: 5.087

3.  Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution.

Authors:  Daisuke Nonaka; Shigeki Kusamura; Dario Baratti; Paolo Casali; Antonello Domenico Cabras; Rami Younan; Juan Rosai; Marcello Deraco
Journal:  Cancer       Date:  2005-11-15       Impact factor: 6.860

4.  Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.

Authors:  Lauren E Rosen; Theodore Karrison; Vijayalakshmi Ananthanarayanan; Alexander J Gallan; Prasad S Adusumilli; Fouad S Alchami; Richard Attanoos; Luka Brcic; Kelly J Butnor; Françoise Galateau-Sallé; Kenzo Hiroshima; Kyuichi Kadota; Astero Klampatsa; Nolween Le Stang; Joerg Lindenmann; Leslie A Litzky; Alberto Marchevsky; Filomena Medeiros; M Angeles Montero; David A Moore; Kazuki Nabeshima; Elizabeth N Pavlisko; Victor L Roggli; Jennifer L Sauter; Anupama Sharma; Michael Sheaff; William D Travis; Wickii T Vigneswaran; Bart Vrugt; Ann E Walts; Melissa Y Tjota; Thomas Krausz; Aliya N Husain
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

5.  Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.

Authors:  Tristan D Yan; Erwin A Brun; Carlos A Cerruto; Namik Haveric; David Chang; Paul H Sugarbaker
Journal:  Ann Surg Oncol       Date:  2006-10-13       Impact factor: 5.344

6.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Authors:  Aliya Noor Husain; Thomas V Colby; Nelson G Ordóñez; Timothy Craig Allen; Richard Luther Attanoos; Mary Beth Beasley; Kelly Jo Butnor; Lucian R Chirieac; Andrew M Churg; Sanja Dacic; Françoise Galateau-Sallé; Allen Gibbs; Allen M Gown; Thomas Krausz; Leslie Anne Litzky; Alberto Marchevsky; Andrew G Nicholson; Victor Louis Roggli; Anupama K Sharma; William D Travis; Ann E Walts; Mark R Wick
Journal:  Arch Pathol Lab Med       Date:  2017-07-07       Impact factor: 5.534

Review 7.  Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.

Authors:  P Jacquet; P H Sugarbaker
Journal:  Cancer Treat Res       Date:  1996

8.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

Authors:  Tristan D Yan; Marcello Deraco; Dario Baratti; Shigeki Kusamura; Dominique Elias; Olivier Glehen; François N Gilly; Edward A Levine; Perry Shen; Faheez Mohamed; Brendan J Moran; David L Morris; Terence C Chua; Pompiliu Piso; Paul H Sugarbaker
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype.

Authors:  Kari Valente; Aaron U Blackham; Edward Levine; Greg Russell; Konstantinos I Votanopoulos; John H Stewart; Perry Shen; Kim R Geisinger; Sahussapont J Sirintrapun
Journal:  Am J Surg Pathol       Date:  2016-09       Impact factor: 6.394

10.  The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry.

Authors:  L Villeneuve; G Passot; O Glehen; S Isaac; F Bibeau; P Rousset; F N Gilly
Journal:  Orphanet J Rare Dis       Date:  2017-02-17       Impact factor: 4.123

View more
  3 in total

Review 1.  Advances in the management of peritoneal malignancies.

Authors:  Vahan Kepenekian; Aditi Bhatt; Julien Péron; Mohammad Alyami; Nazim Benzerdjeb; Naoual Bakrin; Claire Falandry; Guillaume Passot; Pascal Rousset; Olivier Glehen
Journal:  Nat Rev Clin Oncol       Date:  2022-09-07       Impact factor: 65.011

2.  Concurrent alcoholic cirrhosis and malignant peritoneal mesothelioma in a patient: A case report.

Authors:  Liang Liu; Xiao-Yan Zhu; Wen-Jie Zong; Chuan-Lian Chu; Jing-Yu Zhu; Xing-Jie Shen
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

Review 3.  B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.

Authors:  Wolf H Fridman; Maxime Meylan; Florent Petitprez; Cheng-Ming Sun; Antoine Italiano; Catherine Sautès-Fridman
Journal:  Nat Rev Clin Oncol       Date:  2022-04-01       Impact factor: 65.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.